KFKazuto Fukuda

Kazuto Fukuda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kazuto Fukuda has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic impact of worsening of esophageal varices after balloon‐occluded retrograde transvenous obliteration

    by Kazuma Shinkai, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Yasutoshi Nozaki, Kengo Matsumoto, Seiichi Tawara, Kazuto Fukuda, Yuichi Yoshida, Satoshi Tanaka, et al.

    Balloon-occluded retrograde transvenous obliteration (BRTO) is widely performed for treating gastric varices (GVs). However, worsening of esophageal varices (EVs) can be observed after BRTO. This study aimed to investigate the impact of EV worsening on prognosis after BRTO. Overall, 258 patients who underwent initial BRTO for GV treatment between January 2004 and May 2019 at 12 institutions were retrospectively registered. Technical success was achieved in 235 patients (91.1%). Based on the exclusion criteria, 37 patients were excluded, and 198 were evaluated. The cumulative worsening rates of EVs at 1, 2, and 3 years were 39.0%, 59.4%, and 68.4%, respectively. In the univariate Cox proportional hazards model, sex, EV size, history of EV treatment, left gastric vein dilatation, platelet count, aspartate transaminase (AST), alanine aminotransferase (ALT), total bilirubin, albumin, albumin-bilirubin score, prothrombin time-international normalized ratio, fibrosis-4 index, AST to platelet ratio index, and spleen width were significantly associated with worsening of EV after BRTO. Multivariate analysis showed that sex (adjusted hazard ratio [aHR] 1.72; 95% confidence interval [CI] 1.03-2.86; P = 0.04), left gastric vein dilatation (aHR 1.90; 95% CI 1.17-3.10; P = 0.01), ALT (aHR 1.01; 95% CI 1.00-1.03; P = 0.02), albumin (aHR 0.61; 95% CI 0.43-0.87; P < 0.01), and spleen width (aHR 1.02; 95% CI 1.01-1.03; P < 0.01) were independent risk factors for worsening of EV after BRTO. Patients with EV worsening within 1 year after BRTO had a significantly worse prognosis than the other patients (P = 0.007). Early worsening of EV after BRTO was associated with poor prognosis after BRTO.


  • Primary adenosquamous carcinoma of the liver detected during cancer surveillance in a patient with primary sclerosing cholangitis

    by Kazuma Daiku, Kazuto Fukuda, Osakuni Morimoto, Daisuke Takiuchi, Hiromi Shimakoshi, Tadashi Kegasawa, Yoshitaka Yamaguchi, Sachiyo Kogita, Yoshiyuki Sawai, Masanori Nakahara, et al.

    Primary sclerosing cholangitis (PSC) is associated with significant risk for hepatobiliary cancers. Primary hepatic adenosquamous carcinoma (ASC), a rare subtype of cholangiocarcinoma, is composed of both adenocarcinoma and squamous cell carcinoma components. We herein report the case of a patient with PSC who was diagnosed with ASC of the liver during cancer surveillance. A 74-year-old male patient was diagnosed with PSC based on blood chemistry and magnetic resonance cholangiopancreatography findings, and regular surveillance for hepatobiliary cancers was initiated. Four years later, the level of carbohydrate antigen 19–9 rapidly increased, and abdominal imaging studies revealed a cystic mass, 40 mm in diameter, containing a solid component in the right liver lobe. Right lobectomy was performed with a pre-operative diagnosis of cholangiocarcinoma; however, the definitive diagnosis was ASC based on the presence of adenocarcinoma and squamous cell carcinoma components in the resected tumor. The patient did not receive post-operative chemotherapy, but was alive for more than 4 years without recurrence at last follow-up. The present case illustrates that regular surveillance and curative resection might achieve long-term survival in hepatic ASC, which has a poor prognosis.


  • Diagnosis of an intrapancreatic accessory spleen by sonazoid-enhanced ultrasonography

    by Junya Okabe, Kazuto Fukuda, Yasushi Seki, Ryuya Aisaka, Takayuki Iwamoto, Yosuke Yamagata, Noritaka Yamaguchi, Yasushi Matsumoto, Masanori Nakahara, Sachiyo Kogita, et al.

  • Usefulness of ultrasonographic estimation of preperitoneal and subcutaneous fat thickness in the diagnosis of nonalcoholic fatty liver disease in diabetic patients

    by Kazuto Fukuda, Yasushi Seki, Masahiro Ichihi, Takuya Okada, Ayumu Hirata, Sachiyo Kogita, Yoshiyuki Sawai, Takumi Igura, Mamiko Tsugawa, Yasuharu Imai

    Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been regarded as the hepatic manifestation of metabolic syndrome. Abdominal wall fat index (AFI), defined as the ratio of preperitoneal and subcutaneous fat thickness in the abdomen estimated by ultrasonography (US), has been shown to be useful in screening for disorders related to metabolic syndrome. We investigated the relation between AFI and NAFLD/NASH in diabetic patients.


  • Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C

    by Kazuto Fukuda, Yasuharu Imai, Naoki Hiramatsu, Keiko Irishio, Takumi Igura, Yoshiyuki Sawai, Sachiyo Kogita, Yuki Makino, Rui Mizumoto, Yasushi Matsumoto, et al.


    • 1 July 2012
      • Vol. 109  (7) , 1223-9

    [Progression of hepatic fibrosis observed by repeated liver biopsies in an adult case of COACH syndrome].

    by Yuki Makino, Takumi Igura, Yasuharu Imai, Kazuto Fukuda, Yoshiyuki Sawai, Sachiyo Kogita, Naoto Uenoyama, Yoshinori Doi, Shinichi Kiso, Naoki Hiramatsu, et al.

    A 30-year-old man was admitted to Osaka University Hospital for the treatment of gastric varices and assessment of indication for liver transplant. When he was 6 years old, liver dysfunction was pointed out and diagnosed as chronic inactive hepatitis by liver biopsy. At 13 years of age, the second liver biopsy proved congenital hepatic fibrosis (CHF). The third liver biopsy was performed when he was 30 years old, and the progression of hepatic fibrosis was confirmed. Besides CHF, we recognized oligophrenia, cerebellar ataxia, hypoplasia of cerebellar vermis and coloboma, leading to the diagnosis of COACH syndrome. COACH syndrome is quite rare, and our case is especially valuable because he was diagnosed as an adult case and the progression of hepatic fibrosis could be followed through several liver biopsies. We should be aware of COACH syndrome in mind when we encounter CHF patients.

  • Overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis complicated with hepatocellular carcinoma

    by Kazuto Fukuda, Sachiyo Kogita, Yusuke Tsuchimoto, Yoshiyuki Sawai, Takumi Igura, Hideko Ohama, Yuki Makino, Yasushi Matsumoto, Masanori Nakahara, Shin-Ichirou Zushi, et al.


    • 1 June 2011
      • Vol. 108  (6) , 916-27

    [Advances in imaging modalities of hepatocellular carcinoma].

    by Yasuharu Imai, Sachiyo Kogita, Takumi Igura, Yoshiyuki Sawai, Hideko Ohama, Kazuto Fukuda, Yasushi Seki, Manabu Takamura, Masahiro Okada, Takamichi Murakami

  • Sonazoid-enhanced ultrasonography for the diagnosis of an intrapancreatic accessory spleen: A case report

    by Yuki Makino, Yasuharu Imai, Kazuto Fukuda, Yasushi Seki, Sachiyo Kogita, Yoshiyuki Sawai, Takumi Igura, Masanori Kurokawa, Manabu Takamura


  • Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin

    by Yuko Inoue, Naoki Hiramatsu, Tsugiko Oze, Takayuki Yakushijin, Kiyoshi Mochizuki, Kazuto Fukuda, Eiji Mita, Yoshimichi Haruna, Atsuo Inoue, Yasuharu Imai, et al.

    Previous reports demonstrated that amino acid (aa) substitutions in the hepatitis C virus (HCV) core protein are predictors of non-virological responses to pegylated interferon (Peg-IFN) and ribavirin combination therapy. The aim of this study was to investigate the impact of core aa substitutions on viral kinetics during the treatment and relapse after the treatment. The 187 patients with HCV genotype 1 enrolled in this study were categorized into four groups according to core aa substitution patterns: double-wild group (n = 92), Arg70/Leu91; 70-mutant group (n = 42), Gln70/Leu91; 91-mutant group (n = 31), Arg70/Met91; and double-mutant group (n = 22), Gln70/Met91. The relationship between the core aa substitutions and the virological response was examined. Multivariate logistic regression analyses showed that substitution at aa 70 was significantly associated with a poor virological response during the first 12 weeks (decline of <1 log from baseline at week 4, <2 log at week 12), and substitution at aa 91 was significantly associated with detectable HCV RNA at week 24. With respect to relapse, only the ribavirin exposure (odds ratio (OR), 0.77; 95% confidence interval (CI), 0.60–0.98) and HCV RNA disappearance between weeks 13 and 24 (OR, 23.69; 95% CI, 5.44–103.08) were associated independently with relapse, with no correlation being found with the core aa substitutions and relapse. In conclusion, the results showed that core aa substitutions can be strong predictive factors at pretreatment of the non-response, but not for relapse, for virological responders with HCV RNA disappearance during treatment. J. Med. Virol. 83:419–427, 2011.